SynthesisPediatric transplantation2026
Outcomes of ABO-Incompatible Versus ABO-Compatible Liver Transplantation in Pediatric Recipients: An Updated Systematic Review and Meta-Analysis.
Synthesis in Pediatric transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveABO-incompatible (ABO-i) liver transplantation (LT) in children is increasingly used to address organ scarcity, but concerns about immunological, vascular, and biliary complications remain. With evolving desensitization strategies and emerging pediatric data, an updated meta-analysis comparing ABO-i and ABO-compatible (ABO-c) LT is warranted.
methodsPubMed, Embase, and Scopus were searched from inception to June 2026 to include studies evaluating ABO-i versus ABO-c LT in recipients ≤ 18 years of age. Primary outcomes were comparison of 1-, 3-, and 5-year patient and graft survival between the two groups. Secondary outcomes included comparisons of vascular and biliary complications, rejection, cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections, and post-transplant lymphoproliferative disease (PTLD).
resultsSeventeen studies were included. Patient survival was comparable between the two groups at 1 year (risk ratio [RR]: 0.97, 95% confidence interval [CI]: 0.94-1.0, p = 0.07), 3 years (RR: 0.98, 95% CI: 0.94-1.01, p = 0.22) and 5 years (RR: 0.97, 95% CI: 0.88-1.07, p = 0.50). Likewise, graft survival showed no significant differences. Incidence of vascular and biliary complications, acute rejection, CMV and EBV infection, and PTLD also did not differ significantly between groups. Antibody-mediated rejection (AMR) was significantly higher in ABO-i recipients (RR: 20.04, 95% CI: 3.25-123.56, p = 0.001), although this finding was based on only four studies. Overall, heterogeneity was low. Certainty of evidence was rated as very low, primarily due to the observational design of included studies and risk of bias.
conclusionsABO-i LT in pediatric recipients demonstrates survival and complication outcomes comparable to those of ABO-c LT. However, very low certainty of evidence highlights the need for future well-designed prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.